Try Alerts Free   |   Login
Health Care › In Vitro And In Vivo Diagnostic Substances

OCX Price Correlated With Financials For Oncocyte

Free historical financial statements for Oncocyte Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 11 quarters since 2020. Compare with OCX stock chart to see long term trends.

OCX Stock Compared to Quarterly

OCX Income Statement

Revenue, Net:1017000
Revenue Per Share:0.0086
Cost of Goods & Services Sold:1215000
Gross Profit:-1174000
Selling, General & Admin Expense:5763000
Research & Development Expense:4421000
Total Operating Expenses:8047000
Operating Income:-9333000
Income Taxes:null
Net Income:-9555000
Earnings Per Share, Basic:-0.08
Shares Outstanding, Basic Avg:118643821

OCX Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:429000
Change in Accounts Receiveable:188000
Net Cash from Operations:-11352000
Net Cash from Operations Per Share:-0.0957
Net Cash from Financing Activities:-572000
Property, Plant & Equipment Purchases:859000
Purchases of Businesses, Net of Cash:null
Net Cash from Investing Activities:-859000
Net Change in Cash & Equivalents:-12783000

OCX Balance Sheet

Cash and Cash Equivalents:33753000
Accounts Receivable, Net:1990000
Total Current Assets:36636000
Property, Plant & Equipment, Net:9243000
Total Assets:157344000
Accounts Payable:1826000
Total Short-Term Liabilities:12952000
Total Liabilities:75411000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Arno Andrew   Director
250,000 sh at $0
$87,875
Buy
Gutfreund John Peter   Director
75,000 sh at $0
$24,728
Buy
KINGSLEY ALFRED D   Director
25,000 sh at $0
$7,125
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Broadwood Capital Inc
23,353,697 sh
6,003,752 sh
35%
$17,048
-$8,803
Pura Vida Investments, LLC
18,056,274 sh
 
$13,181
Awm Investment Company, Inc.
7,746,557 sh
7,504,690 sh
3103%
$5,655
$5,295
Vanguard Group Inc
4,356,702 sh
10,172 sh
0%
$3,180
-$731
Defender Capital, LLC.
2,551,980 sh
-37,400 sh
-1%
$1,883
-$447
Blackrock Inc.
2,305,331 sh
-38,095 sh
-2%
$1,682
-$426
Orbimed Advisors LLC
1,882,768 sh
-955,032 sh
-34%
$1,374
-$1,179
Geode Capital Management, LLC
994,954 sh
21,632 sh
2%
$726
-$149
Schonfeld Strategic Advisors LLC
749,700 sh
-207,700 sh
-22%
$547
-$315
Millennium Management LLC
721,386 sh
-274,783 sh
-28%
$527
-$369
Penbrook Management LLC
563,350 sh
-12,400 sh
-2%
$411
-$107
Goldman Sachs Group Inc
381,532 sh
-160,451 sh
-30%
$279
-$208
Act Capital Management, Lllp
330,000 sh
 
$241
State Street Corp
281,845 sh
-45,300 sh
-14%
$206
-$88
Northern Trust Corp
208,799 sh
-343,110 sh
-62%
$152
-$670
Bridgeway Capital Management Inc
205,300 sh
 
$150
Lpl Financial LLC
138,841 sh
70,025 sh
102%
$101
-$2
Fort Sheridan Advisors LLC
135,000 sh
 
$99
Morgan Stanley
109,343 sh
-39,099 sh
-26%
$80
-$54
CALIBER WEALTH MANAGEMENT, LLC
75,120 sh
 
$55
COMPANY PROFILE
1.
Organization, Description of the Business and Liquidity

Oncocyte
Corporation (“Oncocyte”), incorporated in 2009 in the state of California, is a molecular diagnostics company focused on
developing and commercializing proprietary laboratory-developed tests (“LDTs”) to serve unmet medical needs across the cancer
care continuum. Oncocyte’s mission is to provide actionable information to physicians and patients at critical decision points
to optimize diagnosis and treatment decisions, improve patient outcomes, and reduce overall cost of care. Oncocyte has prioritized lung
cancer as its first indication. Lung cancer remains the leading cause of cancer death in the United States, despite the availability
of molecular testing and novel therapies to treat patients.

Oncocyte’s
first product for commercial release is a proprietary treatment stratification test called DetermaRx™ that identifies which patients
with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate.
Beginning in September 2019 through February 23, 2021, Oncocyte held a 25 % equity interest in Razor Genomics, Inc. (“Razor”),
a privately held company, that has developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte
is commercializing as DetermaRx™. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding
shares of common stock of Razor and paid the selling shareholders in total $ 10 million in cash and issued them Oncocyte common stock
having a market value of $ 5.7 million on that date. As a result of the purchase of the Razor common stock, Oncocyte is now the sole shareholder
of Razor. The acquisition of the remaining equity interests has been accounted for as an asset acquisition in accordance with Accounting
Standards Codification (“ASC”) Topic 805-50, Business Combinations. See Note 3 for a full discussion of the Razor
asset acquisition.

Oncocyte
completed its acquisition of Insight Genetics, Inc. (“Insight”) on January 31, 2020 (the “Insight Merger Date”)
through a merger with a newly incorporated wholly owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of
an Agreement and Plan of Merger (the “Insight Merger Agreement”). Prior to the Insight Merger, Insight was a privately held
company specializing in the discovery and development of the multi-gene molecular, laboratory-developed diagnostic tests that Oncocyte
has branded as DetermaIO™. DetermaIO™ is a proprietary gene expression assay with promising data supporting its potential
to help identify patients likely to respond to checkpoint inhibitor drugs. Insight has a CLIA-certified diagnostic laboratory with the
capacity to support clinical trials or assay design on certain commercially available analytic platforms that may be used to develop
additional diagnostic tests. Insight also performs Pharma Services in its CLIA-certified laboratory for pharmaceutical and biotechnology
companies, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker
tests (“Pharma Services”). The Insight Merger has been accounted for using the acquisition method of accounting in accordance
with ASC 805, which requires, among other things, that the assets and liabilities assumed be recognized at their fair values as of the
acquisition date. See Note 3 for a full discussion of the Insight Merger.

On
April 15, 2021 (the “Chronix Merger Date”), Oncocyte completed its acquisition of Chronix Biomedical, Inc. (“Chronix”)
pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15,
2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware
corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix, the stockholders party to the Chro

Data imported from Oncocyte Corp SEC filings. Check original filings before making any investment decision.